Johnson & Johnson(NYSE:JNJ) announced on Wednesday that it expects to begin a phase 1/2a clinical trial of its COVID-19 vaccine candidate Ad26.COV2-S, recombinant, in the second half of July. The…
Read More
Johnson & Johnson to Begin Coronavirus Vaccine Clinical Trial in July
